Paragon 28 (FNA): Debts to Book Capitalization

Corporate company logo of Paragon 28 Inc. (FNA)

Paragon 28, Inc. (FNA) relies on a fabless model with shipment control managed through its own hub. The financial leverage trend on the balance sheet via GURU.Markets confirms stability, where 0.87 represents the latest metric reading. Revenues depend on insurance reimbursements and physician training, while outsourcing the production of titanium systems to external factories minimizes operational design risks.

Paragon 28 Inc. - FNA Debts to Book Capitalization (period 07/04/2022 - 04/26/2025)
Brand item of Paragon 28 Inc.

Paragon 28, Inc. (FNA) dominates a niche segment of foot and ankle implants, ensuring high operational efficiency. This success is reflected in the metric structure by comparing all creditor obligations against the net asset value. The indicator measures the extent to which business development depends on borrowed funds relative to equity. High leverage can accelerate expansion but increases financial risks. The trend in the ratio of the company's financial debt to balance sheet capital allows for an assessment of this strategy's sustainability.

Competitors of Paragon 28, Inc.

Boston Scientific - Debts to Book Capitalization|Debt to Book Value edwards.com EW|Debts to Book Capitalization RMD (ResMed)|PODD - Debts to Net Assets|ZBH: Debts to Book Capitalization|COO (CooperSurgical) - Debts to Book Capitalization|Debt to Book Capitalization Ratio Align Technology, Inc.|Debt to Book Capitalization Ratio globusmedical.com|TMDX (TransMedics Organ Care System) - Debts to Book Capitalization|Debts to Net Assets Alphatec Holdings ATEC|Artivion Inc (AORT) - Debt to Book Value|Debts to Book Capitalization Ratio Enovis Inc. ENOV|IART (Integra LifeSciences) - Debts to Book Capitalization|ESTA - Debts to Book Value|Debts to Book Capitalization Beta Bionics|Debt to Book Value Ratio IRADIMED Corp|EMBC - Debt to Book Value|Debt to Net Assets Ratio TNDM|Debt to Book Capitalization Ratio AXGN (AxoGen, Inc.)|Debt to Book Value si-bone.com (SIBN)|OFIX: Debts to Book Capitalization|Debts to Book Value Bioventus Inc BVS|OrthoPediatrics Inc. (KIDS) - Debts to Book Capitalization|TMCI - Debt to Book Value Ratio|Strata Critical Medical Inc - Debts to Book Capitalization|carlsmed.com (CARL) - Debts to Net Assets|Debts to Book Capitalization RXST|Debt to Book Value ClearPoint|Debts to Book Capitalization STXS|Debts to Book Capitalization STIM (Neuronetics, Inc)|Debt to Book Capitalization Ratio Sight Sciences, Inc. SGHT|OBIO - Debt to Book Capitalization Ratio|Debt to Book Value Anika (ANIK)|NSPR - Debt to Net Assets Ratio|Debts to Book Capitalization ZJYL|VANI (Vivani Medical) - Debts to Book Value|Xtant Medical Holdings, Inc. - Debt to Book Capitalization Ratio|Debt to Net Assets n1mtc.com (NMTC)|Debt to Book Value MODD|Debts to Book Capitalization Myomo Inc. (MYO)|Debts to Book Capitalization COCH|Vivos Therapeutics Inc - Debts to Net Assets|Debt to Book Capitalization Ratio enVVeno Medical|SINT: Debts to Book Capitalization Ratio|TNON (Tenon Medical) - Debt to Book Capitalization Ratio|ReWalk Robotics (LFWD) - Debt to Book Value|Debts to Book Capitalization AMIX (Autonomix Medical Inc.)|Debts to Book Value IVF|Debt to Book Capitalization Ratio Bone Biologics BBLG|Debt to Book Value Ratio axonics.com AXNX|Debt to Book Value BIOLASE (BIOL)|Dynatronics Corp - Debt to Book Capital|Debt to Book Capitalization Ratio INVO Bio